At home in Southern Germany, the passionate stock exchange expert has been accompanying the capital markets for about twenty years. With a soft spot for smaller companies, he is constantly on the lookout for exciting investment stories. That it depends thereby less on large names, but on the future potential and whether the market also recognizes these perspectives, was one of its first learnings at the stock exchange.
On these pages, Nico examines current events at listed companies and takes a closer look at companies that are traded under the radar of the market, in addition to well-known securities.
In order to be able to take advantage of speculative opportunities on the stock exchange, Nico not only focuses on a balanced asset allocation of defensive and opportunity-oriented securities, but also on an intact risk management. "In addition to position size and entry in several tranches, investors should also develop a sense of timing and get to know a stock better before investing," says the columnist.
Commented by Nico Popp
Commented by Nico Popp on September 27th, 2021 | 10:46 CEST
BioNTech, Meta Materials, Bayer: Rich with innovations
A new car manufacturer or a new networked fitness device can trigger hype on the stock market. But the opportunities are even greater when companies bring genuine innovations to market. These include new active ingredients, pharmacological processes or pioneering achievements by engineers. We present innovators of yesterday, today and tomorrow and shed light on their growth prospects.
Read
Commented by Nico Popp on September 24th, 2021 | 10:26 CEST
VERBIO BioEnergie, Sierra Grande Minerals, Barrick Gold: Where timing is almost irrelevant
The markets have been in a celebratory mood since the crash following the outbreak of the pandemic. Slowly, however, critical voices are multiplying. Events such as the imbalance of China Evergrande and also the rising inflation are worrying investors. And now, the US Federal Reserve is threatening to raise interest rates in the coming year. How should investors deal with this situation? We present three hot stocks and explain how they fit the market.
Read
Commented by Nico Popp on September 23rd, 2021 | 11:21 CEST
China Evergrande, MAS Gold, Barrick Gold: How to find crisis insurance
The disaster surrounding the Chinese real estate developer China Evergrande is spreading far and wide - even the Deutsche Bank share took a beating at the start of the week. The concerns are obvious: if the Chinese real estate market has to put on the brakes, companies here in Germany could also suffer indirectly. No matter what happens with China Evergrande, the case shows that it pays for investors to hedge against black swans. We explain how this works.
Read
Commented by Nico Popp on September 22nd, 2021 | 12:04 CEST
Nordex, PuriflOH, JinkoSolar: Investing in a better world
To make the world a better place. That is the concern of all entrepreneurs - although one can no doubt argue about innovations in detail. There is no doubt about renewable energy and clean water. Every innovation in these areas pays off not only monetarily but in a variety of ways. We profile three stocks that are doing good.
Read
Commented by Nico Popp on September 22nd, 2021 | 10:28 CEST
BP, Saturn Oil + Gas, Gazprom: Where growth meets low valuations
The climate turnaround is coming, but it will not happen overnight. One raw material that will be needed for a long time to come is oil. OPEC recently increased its demand forecast for 2022 by 4.2 million barrels - every day. The oil companies, which are currently valued low on the stock market, will therefore continue to earn good money for a long time to come. But here, too, the companies with the edge are those that are flexible and have a sustainable focus. We present three stocks.
Read
Commented by Nico Popp on September 21st, 2021 | 10:37 CEST
China Evergrande, Desert Gold, Deutsche Bank: What investors need to watch out for now
When the real estate bubble burst in the US more than ten years ago, the crisis was already looming months ahead. Some hedge funds fell to their knees. In addition, there were other indications that only a few market experts heeded. Today, the situation is similar. Many market participants see the fate of the Chinese real estate group Evergrande as an isolated event - similar to the proverbial sack of rice. But the risk of at least a temporary shock is real. We list risks and outline a possible profiteer.
Read
Commented by Nico Popp on September 20th, 2021 | 10:25 CEST
Drägerwerk, Royal Helium, Bayer: These shares are stepping on the gas
Chemical products and gases are essential products for industry. These primary products are a good indicator of the current economic situation. Shortages are currently prevalent here as well. We explain why and outline three stocks related to this topic.
Read
Commented by Nico Popp on September 17th, 2021 | 13:43 CEST
NEL, dynaCERT, Volkswagen: Where hydrogen has not yet been written off
Will hydrogen become a climate saver in homes? Or will it revolutionize the propulsion technology of ships and trucks? Even if hydrogen has lost some of its fantasy in recent months, the energy carrier is still on the agenda of many inventors and engineers. We introduce three companies that are - sometimes more and sometimes less - involved with hydrogen.
Read
Commented by Nico Popp on September 16th, 2021 | 10:46 CEST
BYD, Kainantu Resources, JinkoSolar: Investing in green technology
Electromobility is on the rise and unstoppable. In July, a survey by E.ON showed that 66% of Germans could imagine buying an e-car. For around 70% of e-car sympathizers, climate protection is the most important argument in favor of an e-car. We highlight three stocks that can benefit from the trend toward more e-mobility.
Read
Commented by Nico Popp on September 15th, 2021 | 12:17 CEST
Valneva, Cardiol Therapeutics, Sartorius: Healthy returns in every market phase
The pandemic has given the healthcare sector a boost. If people were still somewhat hesitant to talk about the digitization of the healthcare system in 2019, the epidemic has clearly revealed where the weaknesses are. New drugs and procedures could also be tested under the new framework conditions. If nothing else, the industry is getting renewed attention as a result. We outline three companies and explain whether the shares have prospects or not.
Read